Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal

Gilead Sciences and Arcellx have been collaborating on the multiple myeloma cell therapy anito-cel since 2022. This therapy was designed to provide better safety, which would be an advantage over Carvykti, the blockbuster multiple myeloma product marketed by Johnson & Johnson and Legend Biotech. The post Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma…

Read More

Health Insurer Financial Performance in 2024

This analysis of trends in health insurers’ financial data shows that insurers’ gross margins per enrollee dipped slightly in 2024 across four markets, remaining highest in the Medicare Advantage market, followed by the individual (non-group) market, the fully insured group (employer) market, and Medicaid managed care. The analysis also examines insurers’ medical-loss ratios across the…

Read More